The Number Nobody Records

Ask a haematology unit how long a marrow procedure takes and the answer is an estimate. Ask how much it hurts and the answer is an impression. Ask which needle size was used and the answer may not be recorded at all.

This is unusual. In almost every other invasive procedure, duration, attempts, and patient-reported discomfort are tracked, because they are the measures that reveal whether a device or a technique is working. Marrow procedures are frequently exempt, and the exemption hides a straightforward finding: size selection is one of the few variables under the unit's control that measurably changes time and pain.

What Size Changes in the Procedure Itself

Duration is composed of preparation, anaesthetic infiltration, puncture and advancement, aspiration, core capture if required, and haemostasis. Size affects the middle three.

A large-bore instrument with a robust bevel crosses dense cortex with fewer advancements, reducing the number of repositioning episodes - the main driver of prolonged procedures. A large lumen also collects the required volume quickly, shortening the aspiration phase. Against this, a larger instrument requires more time for haemostasis and produces more post-procedural aching, and in cellular marrow it invites over-aspiration, which then requires a repeat sample.

A fine instrument reduces trauma and haemostasis time, but slows aspiration, increases the chance of obstruction, and in dense or fibrotic bone increases the likelihood of a second pass, which is the single largest contributor to total procedure time.

Length affects duration less obviously but no less really. An instrument that is too short forces a change of needle mid-procedure; one that is too long without a depth guard encourages cautious incremental advancement, which is safe but slow.

Pain is a function of the same variables viewed from the patient's side. Periosteal pressure during cortical penetration dominates the experience, so the number of advancement attempts matters more than the diameter. Multiple infiltration episodes, from a repeat puncture, compound it.

Classifying the Trade-offs by Size Band

The middle of the range, 13G to 15G, is where time and pain are best balanced in ordinary adult anatomy: adequate flow, adequate stiffness, one puncture, controlled haemostasis.

The large end, 8G to 11G, buys speed in difficult bone at the cost of post-procedural discomfort. It is the correct choice when the alternative is repeated attempts, and the wrong choice as a default.

The fine end, 16G to 18G, buys reduced trauma and faster recovery at the cost of procedural time and obstruction risk. It is correct where the marrow is cellular and the patient is small, and incorrect where the marrow is fibrotic.

Configuration modifies all three. A combined aspiration-biopsy instrument removes an entire second puncture from the timeline, which shows up in audit as a step change in both duration and pain scores. A depth guard reduces the frequency of over-advancement, which shortens recovery.

Building the Measurement Into Practice

The first step is recording. For every procedure, document the gauge and length used, the site, the number of skin punctures, the number of advancement attempts, the aspirate volume drawn, whether a core was obtained, and whether a repeat was required. This takes under a minute and makes everything else possible.

The second step is timing. Record the interval from first needle contact to dressing applied. Do not attempt to time preparation; the procedural segment is what varies with device and technique.

The third step is pain measurement. A simple numeric rating scale at one hour and at twenty-four hours captures the clinically relevant window, and it is the measure patients themselves volunteer. Where paediatric patients are involved, use the unit's standard observational scale.

The fourth step is periodic review. Aggregate by gauge, by length, by operator, and by lot. The patterns that emerge are consistent and often surprising: a size that is rarely used but responsible for most repeat attempts, or a lot whose specimens are repeatedly haemodiluted.

Then change one thing at a time. Introducing a combined instrument and a new supplier simultaneously makes the audit uninterpretable.

What the Numbers Usually Show

Units that begin measuring typically find three things.

First, repeat punctures concentrate in a small number of cases with identifiable causes - a size too fine for the cortex, a length too short for the habitus, or a lumen that obstructed. All three are addressed by stock and specification changes rather than by training.

Second, aspiration volume correlates with haemodilution more strongly than gauge does. Capping volume and using separate aliquots improves specimen quality and shortens the time to a reportable result, which reduces the total episode length even though the procedure itself is unchanged.

Third, procedure time is dominated by the number of advancement attempts rather than by needle diameter. A sharp, well-aligned instrument that reaches the target in one controlled advance is faster than a larger instrument used hesitantly, which inverts the intuition that bigger means quicker.

A fourth finding concerns pain scores: they track attempts and infiltration episodes almost exactly, and track diameter only weakly once attempts are accounted for. Patients remember the number of times something happened, not the size of the needle.

Turning Measurement Into Specification

Once a unit has data, the size discussion becomes factual. A gauge that produces repeat attempts in dense bone is replaced or supplemented. A length that generates aborts in heavier patients is stocked. A supplier whose lots correlate with dry taps is re-examined at incoming inspection.

This is also where buyers gain leverage. A supplier asked to improve a product will comply with adjectives. A supplier shown that a specific size generates a disproportionate share of failed procedures has a specific problem to solve, and the conversation changes.

Two measurement details improve the data without adding burden. Record the time of first needle contact and the time of dressing separately from the procedure start and end, because room turnover and documentation inflate the latter and mask device effects. And ask about pain at the moment of aspiration as well as at one and twenty-four hours, since aspiration discomfort reflects lumen behaviour and cortical discomfort reflects advancement, and the two point to different corrective actions.

Units that adopt even this minimal dataset usually find that their estimate of average procedure duration was wrong by several minutes in both directions, and that the variance between operators using the same size is smaller than the variance between sizes. That second finding is what makes a size standard defensible to clinicians who suspect standardisation of limiting their judgement. A size standard that reduces variance without improving the mean is still a genuine improvement, because it makes outcomes predictable for patients and planners alike.

Outlook and Recommendations

Patient-reported experience is becoming a reported quality metric in more systems, and procedure time is a visible cost in outpatient settings. Both trends will push marrow procedures toward measurement, and measurement will push size selection from habit toward specification.

Three recommendations follow. Record gauge, length, attempts, and volume on every procedure; without the record, no improvement is attributable. Measure pain at one and twenty-four hours rather than relying on impression. Review quarterly by gauge and by lot, and change one variable at a time.

Suppliers should expect to be asked for evidence rather than assertion: patency limits, bevel tolerance, and dimensional records per lot. Those who can supply them will win business on performance rather than on price.

A needle size is a decision made months before a procedure and judged during it. Measuring the outcome is the only way to know whether the decision was right.